

AMENDMENT

U.S. Appln. No. 09/722,438

*sub D2*  
~~58.3~~ (Amended) ~~The substantially optically pure dextrorotatory isomer according to~~  
~~claim 57~~, wherein the pharmaceutically acceptable salt is a salt of a mineral acid, or a substituted  
derivative thereof, selected from the group consisting of hydrochlorides, sulfates, nitrates, and  
phosphates.

*C1*  
*sub D2*  
~~58.4~~ (Amended) ~~The substantially optically pure dextrorotatory isomer according to~~  
~~claim 57~~, wherein the pharmaceutically acceptable salt is a salt of an organic acid, or a  
substituted derivative thereof, selected from the group consisting of acetates, propionates,  
succinates, benzoates, fumarates, tartrates, theophyllineacetates, salicylates, and  
phenolphthalinates.

*sub D1*  
~~58.2~~ (Amended) A pharmaceutical composition comprising an effective amount of the  
~~substantially optically pure dextrorotatory isomer of 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-~~  
piperazinyl)-carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine, or a pharmaceutically  
acceptable salt thereof, and a pharmaceutically acceptable carrier.

*C2*  
~~58.5~~ (Amended) The pharmaceutical composition according to claim ~~58.2~~, wherein the  
pharmaceutically acceptable salt is a salt of a mineral acid, or a substituted derivative thereof,  
selected from the group consisting of hydrochlorides, sulfates, nitrates, and phosphates.

~~58.6~~ (Amended) The pharmaceutical composition according to claim ~~58.2~~, wherein the  
pharmaceutically acceptable salt is a salt of an organic acid, or a substituted derivative thereof,  
selected from the group consisting of acetates, propionates, succinates, benzoates, fumarates,  
tartrates, theophyllineacetates, salicylates, and phenolphthalinates.

AMENDMENT

U.S. Appln. No. 09/722,438

<sup>1</sup>66. (Amended) The pharmaceutical composition according to claim <sup>2</sup>63, wherein the therapeutically effective amount of ~~the substantially optically pure dextrorotatory isomer of~~ 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)-carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine, or a pharmaceutically acceptable salt thereof, is from about 2.5 mg to about 15 mg.

<sup>8</sup>67. (Amended) The pharmaceutical composition according to claim <sup>2</sup>63, wherein the pharmaceutically acceptable carrier comprises a diluent.

Please add the following additional claim:

<sup>3</sup>68. (New) 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine, or a pharmaceutically acceptable salt thereof, in the form of its dextrorotatory isomer and essentially free of its levorotatory isomer.--